| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 11,701 | 27,492 | ||
| Marketable securities | 6,971 | - | ||
| Accounts receivable | 387 | 532 | ||
| Deposits, current portion | 1,747 | 470 | ||
| Prepaid expenses and other current assets | 3,114 | 2,350 | ||
| Foreign withholding tax receivable | 1,899 | - | ||
| Total current assets | 25,819 | 30,844 | ||
| Total property and equipment | 3,904 | - | ||
| Less accumulated depreciation | 3,597 | - | ||
| Property and equipment, net | 307 | 454 | ||
| Operating lease right-of-use asset | 4,602 | 5,118 | ||
| Foreign withholding tax receivable | - | 1,899 | ||
| Deposits | 667 | 1,956 | ||
| Restricted cash | 153 | 153 | ||
| Other long-term assets | 96 | 283 | ||
| Total assets | 31,644 | 40,707 | ||
| Accounts payable | 2,348 | 3,627 | ||
| Accrued expenses | 1,871 | 1,518 | ||
| Research and development contract liability, current portion | 7,816 | 9,579 | ||
| Operating lease liabilities, current | 2,031 | 2,114 | ||
| Current portion of long-term debt, net | 1,458 | 2,416 | ||
| Total current liabilities | 15,524 | 19,254 | ||
| Operating lease liabilities, non-current | 2,684 | 3,104 | ||
| Other long-term payable | 190 | 190 | ||
| Total liabilities | 18,398 | 22,548 | ||
| Common stock, 0.001 par value 300,000,000 shares authorized 77,781,743 and 61,819,101 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 78 | 76 | ||
| Additional paid in capital | 383,218 | 380,686 | ||
| Accumulated other comprehensive loss | 1 | - | ||
| Accumulated deficit | -370,051 | -362,603 | ||
| Total stockholders' equity | 13,246 | 18,159 | ||
| Total liabilities and stockholders' equity | 31,644 | 40,707 | ||
Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc. (CUE)